Pharmacy

Patient risk can improve value-based cancer care. Find out how.

How managed care organizations manage opioid utilization and some of the limitations to those management strategies was a hot topic at the AMCP Annual Meeting.

The correct approach to take when creating a specialty pharmacy network is a key issue for healthcare executives.

Numerous specialty medications, generics, and biosimilars, are expected to be approved this year for cancer, inflammatory and autoimmune diseases, and other indications.

Medical marijuana’s therapeutic evidence base remains nascent and controversial but the regulatory landscape is evolving rapidly.

A study from Walgreens provides a benchmark of basal insulin treatment persistence across different payers in the United States.

On March 10, the White House announced that President Donald Trump selected Scott Gottlieb, MD, who has worked for FDA in the past, as his choice to head the FDA. Here are five things managed healthcare executives should know about the pick.

Here are four of the top benefits of incorporating behavioral health management into care management plans for members with chronic conditions.

Our policy analyst weighs in on a new drug industry PR campaign that attempts to shift the blame for high drug costs.

Here are four ways that health plans can improve their internal processes for collecting provider data.

Here are five critical regulations that executives can begin to prepare for today.

Researchers create a set of recommendations for transparency at the agency in five principal areas.

Include medication-assisted treatment high on the list of clinical tools used to treat opioid addiction.

ACA repeal or replacement must focus on how to preserve mental health services and pharmacy access.

New treatment indications are under investigation for the use of cannabinoid-based drugs.

The proliferation of specialty drugs has prompted new techniques for keeping costs in tow.

New treatment indications are under investigation for the use of cannabinoid-based drugs. Are you ready?

A Precision for Value survey highlights what can be done in order to encourage payers to ease coverage policies for these drugs in the next wave of HCV treatment.

Report highlights spending trends in key areas, including specialty medications, oncology, diabetes, and inflammatory conditions.

Scott Winiecki, MD, of the FDA Center for Drug Evaluation and Research, shares how the FDA is working to address the opioid epidemic.

How can physicians, already struggling to keep up with mounting regulations and larger patient loads, use PDMPs in more effective and efficient ways?

Experts share updates on new diabetes medications, and provide an overview of what’s coming.

A new report has troubling findings for payers, providers, and technology companies. Here are the key takeaways, and reactions from experts.

The proposed megamerger has been shot down. Find out what it means for healthcare execs.

Here are three pharmacy challenges facing healthcare executives and a two-pronged solution to help solve them.

Consider these tactics that analyze and address medical errors at a system level.

Cancer drug costs remain the most critical challenge in care, among other things.

HHS secretary nominee Tom Price has voiced opposition to bundled payments. One expert talks about mandatory and the possibility of voluntary bundled payments.

By deploying a proactive, year-round strategy that aligns data analytics with a focused approach for addressing gaps in care, your organization can turn routine quality measurement and reporting activities into a true strategic advantage by ensuring that quality measurably improves across key metrics.

Find out about the latest treatment and drug pipeline developments